1. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
- Author
-
Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, and Hingorani SR
- Subjects
- Animals, Carcinoma, Pancreatic Ductal pathology, Disease Models, Animal, Genes, p53, Humans, Mice, Pancreatic Neoplasms pathology, Proto-Oncogene Proteins p21(ras) genetics, Smad4 Protein genetics, Carcinoma, Pancreatic Ductal metabolism, Core Binding Factor Alpha 3 Subunit metabolism, Neoplasm Metastasis genetics, Pancreatic Neoplasms metabolism
- Abstract
For the majority of patients with pancreas cancer, the high metastatic proclivity is life limiting. Some patients, however, present with and succumb to locally destructive disease. A molecular understanding of these distinct disease manifestations can critically inform patient management. Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras(G12D/+);Trp53(R172H/+) pancreatic ductal adenocarcinomas while increasing their proliferation. Subsequent loss of heterozygosity of Dpc4 restores metastatic competency while further unleashing proliferation, creating a highly lethal combination. Expression levels of Runx3 respond to and combine with Dpc4 status to coordinately regulate the balance between cancer cell division and dissemination. Thus, Runx3 serves as both a tumor suppressor and promoter in slowing proliferation while orchestrating a metastatic program to stimulate cell migration, invasion, and secretion of proteins that favor distant colonization. These findings suggest a model to anticipate likely disease behaviors in patients and tailor treatment strategies accordingly., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF